Postpartum depression isn’t just a mother’s battle—new study says dads are facing it too. Key signs to watch out for; expert ...

Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal ...

There was, however, one shining exception: The two days my new family spent at the Ahma & Co postnatal retreat at the Waldorf ...

Masaba Gupta shares her postpartum journey returning to work before 40 days Discover the importance of recovery bonding and ...

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's ...

With biting honesty and vivid prose, Sarah Hoover’s memoir dismantles the glossy veneer of motherhood. Arno Reyes Baetz for ...

Sage Therapeutics, Inc. (Nasdaq: SAGE) saw its stock price soar by an impressive 33.87%, reaching $7.43 during Monday’s premarket trading session. The surge came on the heels of the company’s ...

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvae’s launch in postpartum depression.

Biogen is looking to augment growth by hunting for biotechs with drugs in mid- and late-stage clinical development.

The University of Virginia's Dr. Anita Clayton has been a primary investigator for nearly every antidepressant approved in ...

Mizuho analyst Uy Ear says that while Biogen’s (BIIB) offer for Sage Therapeutics (SAGE) is a 30% premium to Sage’s Friday’s closing price, ...

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...